Northern Trust
ANTX icon

Northern Trust’s AN2 Therapeutics ANTX Stock Holding History

Northern Trust’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
214,921
+171,725
+398% +$739K ﹤0.01% 3451
2026
Q1 		$148K Hold
43,196
– – ﹤0.01% 4021
2025
Q4 		$49.2K Hold
43,196
– – ﹤0.01% 4280
2025
Q3 		$54.9K Hold
43,196
– – ﹤0.01% 4269
2025
Q2 		$45.8K Hold
43,196
– – ﹤0.01% 4245
2025
Q1 		$58.7K Hold
43,196
– – ﹤0.01% 4209
2024
Q4 		$59.6K Buy
43,196
+10,601
+33% +$12.9K ﹤0.01% 4241
2024
Q3 		$34.9K Hold
32,595
– – ﹤0.01% 4268
2024
Q2 		$70.1K Sell
32,595
-3,768
-10% -$8.97K ﹤0.01% 4136
2024
Q1 		$118K Buy
36,363
+3,313
+10% +$36K ﹤0.01% 4033
2023
Q4 		$677K Buy
33,050
+16,415
+99% +$275K ﹤0.01% 3442
2023
Q3 		$267K Buy
+16,635
New +$188K ﹤0.01% 3710
2023
Q2 		– Sell
-76,134
Closed -$751K – 4535
2023
Q1 		$751K Sell
76,134
-4,684
-6% -$52.1K ﹤0.01% 3314
2022
Q4 		$770K Buy
80,818
+43,379
+116% +$581K ﹤0.01% 3355
2022
Q3 		$650K Buy
37,439
+1,042
+3% +$12.1K ﹤0.01% 3427
2022
Q2 		$282K Buy
+36,397
New +$482K ﹤0.01% 3750

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Northern Trust's ANTX Position: Q2 2026 in Review

Northern Trust increased its AN2 Therapeutics (ANTX) stake by 398% in Q2 2026, buying an estimated $739K and bringing the position to 214,921 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3451.

Northern Trust first reported a position in ANTX in Q2 2022 and has held it in 16 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Northern Trust held 214,921 shares of AN2 Therapeutics worth $1.04M as of Q2 2026.
  • Northern Trust bought 171,725 AN2 Therapeutics shares in Q2 2026, an estimated $739K.
  • AN2 Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3451 holding.
  • Northern Trust first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.